AnalysisNews

KRSA today

$37.56+$2.11 (+5.95%)close Nov 20, 2026

Trend

DailyNeutral

4 hourAscending Triangle

1 hourStrong Bullish

15 minStrong Bullish

5 minSymmetric Triangle

Key levels

Support$35.34

Support$32.98

Latest news & SEC filings

AnalystWells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target

EarningsKorsana Biosciences Posts Q3 2026 Results, Issues Update

EarningsKorsana Biosciences posts wider quarterly loss than analysts expected

All KRSA news →

About Korsana Biosciences

Korsana Biosciences is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders. Its lead program, CYC-126, combines two generic intravenous anesthetics with a personalized delivery and brain-monitoring system for treatment-resistant depression, intended for use in hospital settings. The company also holds legacy soluble guanylate cyclase stimulator assets, including praliciguat, which is licensed to Akebia for focal segmental glomerulosclerosis, and olinciguat, for which it seeks licensing partners.

Based on the company's 10-K filed Mar 30, 2026.

Nasdaq · Healthcare

Korsana Biosciences, Inc. (KRSA)

$37.56+2.11 (+5.95%)
WATCHLISTGrade: BRisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
31.5733.0734.5636.0637.56Oct 20Oct 28Nov 5Nov 13
High39.41
Low34.08
Open35.63
Volume235K
Avg Vol174K
VWAP37.34
30d High37.56
30d Low30.07
30d Chg+10.34%

What Is the Price Target for KRSA?

SEPT Low Target

$43.00

SEPT Mid Target

$49.50

SEPT High Target

$70.00

Analyst Consensus

$49.50

Current: $37.56Upside: +31.8%Confidence: 65%Method: Analyst Consensus

Is KRSA a Buy or Sell Right Now?

63
Investability Score
WATCHLIST12-18 months
News summary · last 30 days
Critical news
Nov 5HIGHEarnings: decline/miss

Thesis

  • •Revenue growing 3.7% YoY with ACCELERATING trend — accelerating momentum.

Test your own strategy on KRSA

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on KRSA with SEPT’s own market data.

Start Free Trial →

Is KRSA Overvalued or Undervalued?

Valuation Verdict

OVERVALUED

Methods Used

P/B, Analyst Consensus

Fair Value

$37.85

15

Moat Score

NONE

1/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with KRSA?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

MEDIUM

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

KRSA Growth Story

Revenue YoY

3.7%

3yr Revenue CAGR

-19.3%

EPS Growth YoY

8.26%

FCF Growth YoY

N/A%

Revenue Trend

ACCELERATING

Dark Pool Trades for KRSA

PREVIEW

Recent off-exchange (dark pool) prints for KRSA: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
19:14:56$36.551,000$$37KSELL
18:46:41$37.111,400$$52KMIDPOINT
18:36:53$37.112,101$$78KBUY
16:33:24$37.8511,500$$435KSELL
16:19:59$37.621,143$$43KSELL

5 dark pool trades shown · $$645K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Korsana Biosciences, Inc. (KRSA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →

KRSA — frequently asked questions

What is KRSA stock price today?

Korsana Biosciences, Inc. (KRSA) is at $37.56, up 5.95% (+$2.11) at the Nov 20, 2026 close.

Why is KRSA stock moving today?

Latest KRSA news — Nov 13, 2026: Wells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target · Nov 5, 2026: Korsana Biosciences Posts Q3 2026 Results, Issues Update

What is the KRSA price target?

The average analyst price target for KRSA is $49.50, ranging from $43 to $70, based on 4 analysts. Latest: Wedbush initiates on Oct 5, 2026.

What do analysts rate KRSA?

Analyst ratings for KRSA: 0 Buy, 5 Hold, 0 Sell — consensus Hold.

Did KRSA beat earnings?

KRSA last reported on Nov 5, 2026: EPS -$3.19 vs -$0.85 expected — a miss of 275.3%.

What are KRSA support and resistance levels?

Support: $35.34, $32.98, $30.45.

What are insiders doing with KRSA?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on KRSA?

Nov 13, 2026: Wells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target · Nov 5, 2026: Korsana Biosciences Posts Q3 2026 Results, Issues Update · Nov 5, 2026: Korsana Biosciences posts wider quarterly loss than analysts expected